참고문헌
- Shapiro SS. Treating thrombosis in the 21st century. N Engl J Med 2003;349:1762-1764. https://doi.org/10.1056/NEJMe038152
- Sinauridze E.I., Panteleev M.A., Ataulla khanov F.I.Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis 2012;23:482-493. https://doi.org/10.1097/MBC.0b013e328355c9cb
- righton T.: New oral anticoagulant drugs- mechanisms of action, Aust Prescr 2010;33:38-41. https://doi.org/10.18773/austprescr.2010.017
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. https://doi.org/10.1056/NEJMoa0905561
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891 . https://doi.org/10.1056/NEJMoa1009638
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992. https://doi.org/10.1056/NEJMoa1107039
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104. https://doi.org/10.1056/NEJMoa1310907
- Lip GY, Camm AJ, Hylek EM, et al. Non-vitaminK antagonist oral anticoagulants: an appeal for consensus on terminology. Chest 2014;145:1177-1178. https://doi.org/10.1378/chest.13-2951
- Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014;8:789-798. https://doi.org/10.2147/DDDT.S45644
- Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharma cokinetic effects in healthy subjects. Br J Clin Pharmaocl 2013;76:455-466. https://doi.org/10.1111/bcp.12075
- Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010;38:448-458. https://doi.org/10.1124/dmd.109.029694
- F. Schiele, J. van Ryn, K. Canada, et al., A specific antidote for dabigatran: functional and structural characterization, Blood 2013;121: 3554-3562. https://doi.org/10.1182/blood-2012-11-468207
- DeWald TA, Becker RC: The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis 2014;37:217-233. https://doi.org/10.1007/s11239-013-0967-z
- Wang L, Zhang D, Raghavan N, et al. In vitro assessment of met abolic drug-drug interaction potential of apixaban through cy tochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010;38:448-458. https://doi.org/10.1124/dmd.109.029694
- A. Greinacher, T. Thiele, K. Selleng, Reversal of anticoagulants: an overview of current developments, Thromb. Haemost. 2015;113:931-942. https://doi.org/10.1160/TH14-11-0982
- C.V. Pollack Jr., P.A. Reilly, J. Eikelboom, et al., Idarucizumab for Dabigatran Reversal, N. Engl. J. Med. 2015;373;511-520. https://doi.org/10.1056/NEJMoa1502000
- G. Lu, F.R. DeGuzman, S.J. Hollenbach, et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nat.Med.2013;19: 446-451. https://doi.org/10.1038/nm.3102
- K. Ghadimi, K.E. Dombrowski, J.H. Levy, I.J. Welsby, Andexanet alfa for the reversal of factor Xa inhibitor related anticoagulation, Expert. Rev. Hematol. 2016;9:115-122. https://doi.org/10.1586/17474086.2016.1135046
- M.L.G. Crowther, G. Lu, J. Leeds, J. Lin, P. Pratikhya, P.B. Conley, S. Connolly, J.T. Curnutte, A phase 2 randomized, double-blind, placebo-controlled trial demonstrat ing reversal of edoxabaninduced anticoagulation in healthy subjects by andexanet alfa (PRT064445): a universal antidote for factor Xa (fXa) inhibitors, Blood 2014;124: 4269. https://doi.org/10.1182/blood.V124.21.4269.4269
- SDCEP: Managementof dental patients taking anticoagulants or antiplatelet drugs: dental clinical guidance. (http://www.sdcep.org.uk/wp-content/uploads/2015/09/SDCEP-Anticoagulants-Guidance.pdf)